McCulloch typically uses 1,5002,000 mg/day clinical protocols often adjust from research doses based on patient presentation, tolerability, and the broader supplement strategy
Some patients experience profound appetite suppression, whilst others notice more modest effects
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
If you have any questions or need assistance, please get in touch with our customer service team
If your skin continues worsening beyond eight weeks without any improvement trend, purging is unlikely the cause